This is the first time a PD-L1 inhibitor and a CTLA-4 inhibitor have been combined, making this regimen the second FDA-approved first-line regimen for treating advanced HCC after “T+A”,which will benefit more patients. Here, CD274 is linked to hepatocellular carcinoma.